These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 22616372)

  • 41. Statin therapy for primary prevention of cardiovascular disease.
    Taylor FC; Huffman M; Ebrahim S
    JAMA; 2013 Dec; 310(22):2451-2. PubMed ID: 24276813
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The past, present, and future of statin therapy.
    Watson KE; Fonarow GC
    Rev Cardiovasc Med; 2005; 6(3):129-39. PubMed ID: 16195686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of dyslipidaemia in patients treated with lipid-modifying drugs in the Netherlands. Part of the dyslipidaemia international survey.
    Strang AC; Kaasjager HA; Basart DC; Stroes ES
    Neth J Med; 2010 Apr; 68(4):168-74. PubMed ID: 20421658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Statin therapy in the elderly: a review.
    Szadkowska I; Stanczyk A; Aronow WS; Kowalski J; Pawlicki L; Ahmed A; Banach M
    Arch Gerontol Geriatr; 2010; 50(1):114-8. PubMed ID: 19217673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
    Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
    Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment with statins in general medicine: dosage and effectiveness. Results of the observational study STATIMED].
    Amouyel P; Lamarque H; Gayet JL
    Arch Mal Coeur Vaiss; 2005 Dec; 98(12):1206-11. PubMed ID: 16435599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statins and the elderly: recent evidence and current indications.
    Schiattarella GG; Perrino C; Magliulo F; Ilardi F; Serino F; Trimarco V; Izzo R; Amato B; Terranova C; Cardin F; Militello C; Leosco D; Trimarco B; Esposito G
    Aging Clin Exp Res; 2012 Jun; 24(3 Suppl):47-55. PubMed ID: 23160507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Treatment with statins].
    Bogsrud MP; Reikvam Å; Retterstøl K
    Tidsskr Nor Laegeforen; 2013 Jun; 133(12-13):1316-9. PubMed ID: 23817262
    [No Abstract]   [Full Text] [Related]  

  • 52. Debate on adverse effects of statins.
    Bifulco M
    Eur J Intern Med; 2014 Oct; 25(8):e95. PubMed ID: 25216633
    [No Abstract]   [Full Text] [Related]  

  • 53. Statin therapy and related risk of new-onset type 2 diabetes mellitus.
    Ruscica M; Macchi C; Morlotti B; Sirtori CR; Magni P
    Eur J Intern Med; 2014 Jun; 25(5):401-6. PubMed ID: 24685426
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary prevention of cardiovascular events in patients with major mental illness: a possible role for statins.
    Andrade C
    Bipolar Disord; 2013 Dec; 15(8):813-23. PubMed ID: 24119211
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reinitiation of statins after statin-associated musculoskeletal symptoms: a patient-centered approach.
    Brito JP; Montori VM
    Circ Cardiovasc Qual Outcomes; 2013 Mar; 6(2):243-7. PubMed ID: 23481527
    [No Abstract]   [Full Text] [Related]  

  • 56. [Benefits and risks for primary prevention with statins in the elderly].
    Joseph JP; Afonso M; Berdaï D; Salles N; Bénard A; Gay B; Bonnet F
    Presse Med; 2015 Dec; 44(12 Pt 1):1219-25. PubMed ID: 26585744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention.
    Mombelli G; Bosisio R; Calabresi L; Magni P; Pavanello C; Pazzucconi F; Sirtori CR
    J Clin Lipidol; 2015; 9(2):226-33. PubMed ID: 25911079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Do statins prevent acute kidney injury?
    Philips B; MacPhee I
    Expert Opin Drug Saf; 2015 Oct; 14(10):1547-61. PubMed ID: 26365784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Statin treatment in primary and secondary prevention--a statement].
    Mach F; Riesen WF; Rodondi N; Von Eckardstein A
    Rev Med Suisse; 2014 Dec; 10(455):2430-3. PubMed ID: 25752015
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An assessment by the Statin Intolerance Panel: 2014 update.
    Guyton JR; Bays HE; Grundy SM; Jacobson TA; The National Lipid Association Statin Intolerance Panel
    J Clin Lipidol; 2014; 8(3 Suppl):S72-81. PubMed ID: 24793444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.